Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
19 hedge funds and large institutions have $5.41M invested in Medicenna Therapeutics Corp. Common Shares in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0.39% more ownership
Funds ownership: 7.94% → 8.33% (+0.39%)
3% less capital invested
Capital invested by funds: $5.56M → $5.41M (-$148K)
5% less funds holding
Funds holding: 20 → 19 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$212K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$55.3K |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$29.1K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
+$26.7K |
| 5 |
GVAG
Great Valley Advisor Group
Wilmington,
Delaware
|
+$20.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IIM
Intact Investment Management
Montreal,
Quebec, Canada
|
-$117K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$26K |
| 3 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
-$17K |
| 4 |
Renaissance Technologies
New York
|
-$8.12K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6.95K |
MDNA Hedge Fund Activity: Q2 2022 in Review
19 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q2 2022, worth a combined $5.41M — down 2.7% from $5.56M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MDNA and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.
The largest buyer was Morgan Stanley, adding an estimated $212K. The largest seller was Intact Investment Management, exiting entirely with an estimated $117K sold.
- 19 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q2 2022, down from 20 in Q1 2022.
- Funds reported $5.41M of Medicenna Therapeutics Corp. Common Shares stock for Q2 2022, down 2.7% quarter-over-quarter.
- 3 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q2 2022 and 4 closed out, a net change of -1 holder.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q2 2022 was Morgan Stanley, an estimated $212K added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q2 2022 was Intact Investment Management, an estimated $117K sold.
Based on aggregated 13F filings for Q2 2022.